Overview

TRimetazidine for acUte on Chronic Liver Failure STudy

Status:
Suspended
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.
Phase:
Phase 1
Details
Lead Sponsor:
Martin Pharmaceuticals
Treatments:
Trimetazidine